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INTRODUCTION
According to the World Health Organization, cancer is the second cause of death
worldwide (12 % of all causes) after cardiovascular diseases. In 2000 there were 10 mil-
lion new cases of cancer worldwide and by 2020 there could be a 50 % increase, to 15
million (1).
Current cancer therapies
Current cancer therapies are either local or systemic treatments. Local treatments in-
clude surgery and radiation therapy. Systemic treatments include chemotherapy, hormo-
ne therapy and biological therapy. There are two problems with these therapies: they are
oncostatic and have poor selectivity (2).
Oncostatic therapies suppress cancer cell growth and proliferation (3). Due to the
fact that current therapies are oncostatic, survival rates for most cancers are generally
unsatisfactory. By the end of the 20th century, 5-year relative survival rates for the 4 most
common cancer sites (prostate, breast, colorectal and lung) were 98 % for prostate cancer
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in males, 15 % for lung cancer in both sexes, 62 % for colorectal cancer in both sexes and
86 % for breast cancer in females (4).
Due to the fact that current cancer therapies have poor selectivity, side effects are
common. Some side effects are minor, resulting in patient discomfort, others, however,
are major (e.g., chemotherapy induced pancytopenia) and require treatment (5).
Future cancer therapies
Future therapies will be most likely molecular cures. They will correct, block or de-
stroy cancer cells by targeting molecular changes that lead to carcinogenesis. Correction
of cancer cells could be achieved by fixing DNA mutations using genetic engineering.
Blocking of cancer cells could be achieved by interfering with transcription and transla-
tion. Destroying cancer cells can be done using oncolytic viruses (6).
The oncolytic properties of some viruses were detected 100 years ago. The first pub-
lished report to establish a link between a virus infection and cancer regression appea-
red in the early 1900’s. In 1912, it was reported in Europe, that a woman’s cervical cancer
improved subsequent treatment to prevent rabies. The woman was bitten by a dog and
was injected with a vaccine made of attenuated rabies virus (7). The first report of posi-
tive results using wild type viruses to treat human cancer were published in the 1950’s
and 1960’s, e.g. adenovirus (AdenoV) in 1956 and Newcastle Disease Virus (NDV) in 1964.
Clinical trials for wild type and mutant oncolytic viruses began in the 1990’s (8). Several
oncolytic viruses have now advanced to late phase clinical trials, e.g., AdenoV H101 phase
III clinical trial for head and neck cancers and NDV MTH-68H phase II clinical trial for
metastatic solid cancers (9). The first oncolytic virus, a genetically modified AdenoV
H101, received regulatory approval in 2005 and was put on the market in China (10).
Oncolytic viruses have two major advantages over current therapies: they are
oncolytic and have high selectivity (11). This is due to the fact that they take advantage
of the intracellular aberrations in signalling pathways that are associated with carcino-
genesis (12). There is one major problem with both wild type and mutant viruses: the
high efficacy in vitro cannot be replicated in vivo. The patient’s antiviral immune respon-
se due to preformed circulating antibodies and T-cell memory from prior exposure to
the virus is blocking virus replication in vivo (13).
In order to be efficacious, in vivo oncolytic viruses should be able to avoid the im-
mune system, reach all cancer cells, kill all cancer cells and leave a long lasting host im-
mune response against cancer cells. As we can easily imagine, an ideal virus must inacti-
vate antibodies (and complement), attach, internalize, replicate and kill cancer cells,
release progenies that will kill all cancer cells, stimulate the host immune response to
cancer cells, not be able to replicate inside normal cells and be able to be inactivated by
drugs (6).
Inactivation of antiviral antibodies can be done by temporary immunosuppression.
There are several classes of immunosuppressive drugs currently available on the market
(14). However, since they are not selective, they cannot be associated with oncolytic vi-
ruses. By inhibiting also cellular immunity, they would prevent the virus from leaving a
long-lasting immune response against cancer relapse. Inactivation of humoral immunity
only could be done by developing biopharmaceuticals that selectively block humoral
immunity without affecting cellular immunity.
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BLOCKING IMMUNITY BY HERPES SIMPLEX VIRUS TYPE 1
GLYCOPROTEINS E AND I
Structure and function of Herpes simplex virus type 1 glycoproteins E and I
Herpes simplex virus type 1 (HSV-1) are one of the most studied viruses. The struc-
ture and function of glycoproteins E (gE) and I (gI) are well known.
Glycoprotein E is a 550 amino acid type I transmembrane glycoprotein that has two
potential N-linked glycosylation sites and contains nine cysteines in the extracellular do-
main, one cysteine in the cleaved signal sequence and another in the transmembrane do-
main. The gene that codes gE (Us8) was identified in 1985 (15). The amino acid region
required for binding antibody (235–380) and for complex formation (235–264) was iden-
tified in 1995 (16).
Glycoprotein I is a 390 amino acid type I transmembrane glycoprotein that contains
three potential N-linked glycosylation sites and a cluster of four cysteine residues in the
extracellular domain. The gene that codes gI (Us7) was identified in 1985 (15). The ami-
no acid region required for complex formation (43–192) was identified in 1997 (16).
Glycoproteins E and I are immune evasion proteins that protect HSV from antibody-
-mediated immune attack. They form a hetero-oligomer complex that binds the fragment
crystallizable (Fc) domain of immunoglobulin G (IgG) in both IgG aggregates and mo-
nomers. While the anti-HSV IgG binds to its target antigen by its fragment antigen bind-
ing (Fab) end, the gE/gI complex binds the IgG Fc end. The process, demonstrated by in
vitro studies, is called bipolar bridging. Antibody bipolar bridging also inhibits comple-
ment activation by the IgG Fc domain (16).
Studies have been done to define the role of gE and gI in immune evasion in vivo. A
mutant HSV was constructed (NS-gE339) that does not bind the Fc domain of IgG, thus
being unable to inactivate IgG through bipolar bridging. Mice were passively immuni-
zed with human anti-HSV IgG and then infected with wild-type and mutant HSV. As
expected, human anti-HSV IgG reduced disease severity and viral titers in mutant-in-
fected but not in wild-type infected mice. These experiments have shown that the gE/gI
complex provides significant protection against antibody mediated immunity in vivo (16).
Therapeutic use of Herpes simplex virus type 1 glycoproteins E and I
HSV-1 gE/gI complex selectively blocks human humoral immunity in vitro and in
vivo without affecting cellular immunity. HSV-1 gE/gI complex is capable of inhibiting
IgG, which composes 75 % of the immunoglobulin pool, both in vitro and in vivo because
it has Fc receptor (FcR) activity (17). HSV-1 usually produces a benign infection, primary
infection resulting in gingivostomatitis and reactivation resulting in recurrent orolabial
lesions (18).
The therapeutic efficacy of a future biopharmaceutical based on HSV-1 gE/gI is due
to the fact that this complex is able to inhibit IgG both in vitro and in vivo. The thera-
peutic safety is due to the fact that HSV-1 infection is usually benign, thus a future bio-
pharmaceutical based on HSV-1 gE/gI should be generating only minor side effects. Fu-
ture work needs to be done before HSV-1 gE/gI can become a biopharmaceutical.
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HERPES SIMPLEX VIRUS TYPE 1 GLYCOPROTEINS E AND I FROM IDEA
TO BIOPHARMACEUTICAL
In order to move HSV-1 gE/gI from medical research into pharmaceutical research
and development, future work must be done in regard to manufacturing, in vitro research,
in vivo research, formulation and in vivo development.
Manufacturing Herpes simplex virus type 1 glycoproteins E and I
The purpose of these studies is to verify whether sufficient quantities of herpes sim-
plex virus type 1 glycoproteins E and I can be manufactured using recombinant tech-
niques. A possible research approach is described below.
Viral HSV-1 DNA that encodes gE and gI (HSV-1gE and HSV-1gI) must be cut from
the HSV-1 genome using restriction enzymes. HSV-1gE and HSV-1gI must be purified
by phenol extraction and ethanol precipitation (19). HSV-1gE and HSV-1gI must be in-
cluded in an expression plasmid construction using, for instance, pUC18 as a vector (20).
The plasmid must be transformed in Escherichia coli bacterial cells (19), where recombi-
nant (r) HSV-1gE and HSV-1gI should be expressed (21). Purification of rHSV-1gE and
rHSV-1gI can be done by cation-exchange chromatography and reversed-phase high per-
formance liquid chromatography (22).
In vitro research studies
These studies will hopefully prove that rHSV-1gE and rHSV-1gI have the ability to
inhibit humoral immunity in vitro. In vitro research studies can be done by using the ro-
settes method.
The rosettes method is an assay used to detect FcR activity for IgG aggregates. Sheep
erythrocytes must be sensitized with subagglutinating concentrations of goat anti-sheep
erythrocyte IgG. Sensitized sheep erythrocytes must be incubated for 2 hours at 37 °C
with Escherichia coli bacterial cells transformed with rHSV-1gE and rHSV-1gI in a ratio of
100:1. Erythrocyte rosette formation can be observed by light microscopy. A rosette is de-
fined as a cell with more or at least four bound erythrocytes bordering its perimeter (23).
In vivo research studies
These studies will hopefully prove that rHSV-1gE and rHSV-1gI have the ability to
inhibit humoral immunity in vivo. These studies also need to determine the optimum
rHSV-1gE and rHSV-1gI dose at which antibody mediated neutralization of oncolytic vi-
ruses is inhibited in vivo in a murine model of cancer.
A murine model of cancer can be prepared by implanting human cancer cells into
mice. Implantation needs to be orthotopic, at the correct anatomical site (e.g., human lung
cancer cells need to be implanted in mice lungs). Orthotopic implantation mimics better
the complexity of cancer behaviour in humans (24). Increasing doses of purified rHSV-
-1gE and rHSV-1gI should be injected into the murine model of cancer before adminis-
tering an oncolytic virus. Increased doses of oncolytic virus should be administered up
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to the maximally tolerated dose (MTD), which is the highest dose that does not cause
unacceptable side effects. MTD differs from oncolytic virus to another (25). A dose-re-
sponse curve should be used to determine for each dose of administered oncolytic virus
the optimum rHSV-1gE and rHSV-1gI dose (26).
Formulation of rHSV-1gE and rHSV-1gI
Before pharmaceutical development can be started, a suitable drug formulation must
be conceived. Since rHSV-1gE and rHSV-1gI is intended to be administered intravenou-
sly, it should be formulated as a sterile injection for intravenous administration. A drug
concentration must be established (for example 1 mg mL–1). Several excipients must be
added, such as an isotonic agent (for example 15 mg glycerol), a conserving agent (for
example 10 mg benzyl alcohol), a pH stabilizer (for example sufficient natrium hydrox-
ide for maintaining pH 4), a protein aggregation inhibitor (for example 9 mg zinc chlo-
ride) and a solvent (for example 9 mg natrium chloride and water for injection add 1
mL) (27).
In vivo development. – These studies will hopefully prove that rHSV-1gE/gI sterile
injection for intravenous administration is efficacious and safe when administered to an-
imals and humans. Non-clinical studies should be done according to the Good Labo-
ratory Practice (GLP) standards (28). Clinical studies should be done according to the
Good Clinical Practice (GCP) standards (29).
CONCLUSIONS
By blocking antibody mediated neutralization of oncolytic viruses, HSV-1 gE/gI
could be used in the adjuvant treatment of cancer for improving the chances of oncolytic
viruses to kill cancer cells in vivo. Although the structure and function of HSV-1 gE/gI
are well known, future work needs to be done in order to obtain a biopharmaceutical
based on recombinant glycoproteins. Manufacturing, therapeutic efficacy and therapeu-
tic safety must be clarified through future research and development.
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S A @ E T A K
Razvoj selektivnih biofarmaceutika iz glikoproteina E i I iz Herpes simplex virusa
tipa 1 koji blokiraju neutralizaciju onkolitskih virusa posredovanu antitijelima
SEPTIMIU BUCURESCU
Terapija karcinoma }e u budu}nosti biti na molekularnoj razini. Biti }e mogu}e pro-
mijeniti, blokirati ili uni{tavati stanice ciljanim utjecanjem na molekularne promjene koje
vode do karcinogeneze. Uni{tavanje stanica karcinoma mo}i }e se ostvariti pomo}u on-
kolitskih virusa. U pomo}noj terapiji karcinoma mo}i }e se koristiti glikoproteini E i I iz
Herpes simplex virusa tipa 1 koji blokiraju neutralizaciju onkolitskih virusa posredova-
nu antitijelima ~ime se pove}avaju {anse da onkolitski virusi uni{te stanice karcinoma in
vivo.
Klju~ne rije~i: terapija karcinoma, glikoproteini E i I, Herpes simplex virusa tipa 1, neutralizacija on-
kolitskih virusa posredovana antitijelima
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